 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
Amplizone™
Amplizone™ has been selected for further development from a series of over
150 proprietary compounds in the company's azonafide series. These compounds
were discovered, synthesized and developed by the company's scientists at
The University of Arizona.
Amplizone belongs to a family (anthracenes) of compounds which interfere
with the ability of the genetic material of the cell, DNA, to replicate. In
preclinical work, it was shown to be unaffected by the multi-drug resistance
(MDR) pathway and the cardiotoxicity which can limit the usefulness of many
drugs of this class. Amplizone has demonstrated efficacy in the treatment of
a variety of solid tumors in animal tumor models. The Company is currently
undertaking the preclinical work required to gain authorization to test the
drug in humans. Upon completion of the pre-clinical work, the company will
further assess the agents' potential for clinical development. Initial
target diseases will be drug-resistant ovarian and breast cancer.
The structure of Amplizone
is shown below:
